Study Evaluating GAP-486 in Non-Sustained Ventricular Tachycardia

• Status: Terminated
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Anti-Arrhythmia Agents

Criteria

INCLUSION CRITERIA:

• Male and female patients, 18 years of age or older, that have experienced an acute ischemic event within 24 hours prior to study entry.

• Patients with a documented history of coronary artery disease or left ventricular dysfunction

• Patients who have experienced an episode of non-sustained ventricular tachycardia within 24 hours of the index ischemic event

EXCLUSION CRITERIA:

• Patients who have had percutaneous coronary intervention (PCI), thrombolytics, or open-heart surgery within 48 hours prior to study entry, or who require it during test article administration

• Patients who have taken another antiarrhythmic medication (other than a beta blocker) within 5 half-lives of the start of test article

• Patients who have a history of torsades de pointes, long QT syndrome, QTc > 0.50